For example, heterogeneity I2 was 70% for pCR in patients receiving nICRT, while I2 reduced to 0% in subgroup of ESCC; I2 was 63% for pCR in patients receiving nICT, while I2 decreased to 0% in subgroup of PD-L1 CPS ≥1 or ≥10 and decreased to 20% in CT regimen with PC/TP. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.